Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: Publication

Performance of neoantigen prediction for the design of TG4050, a patient specific neoantigen cancer vaccine

AACR2020 myvac B. Mallone et al. AACR 2020 Download the poster here Poster Presentation

Published 22 June 2020
Categorized as 2020, Myvac, Publication, publication key en, TG4050

BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti- CTLA4 antibody and GM-CSF to target the tumor microenvironment

Poster BT-001Marchand, Semmrich, Fend et al. Immuno-Oncology summit Download the poster here Poster Presentation

Published 11 March 2020
Categorized as 2020, BT-001, Publication

Non-clinical and clinical safety of MVA-based immunotherapy products targeting cancer and infectious diseases

https://www.transgene.com/wp-content/uploads/posters/Poster-actox2019.pdfClémentine Spring-Giusti et al.American College of Toxicology – 40th Annual MeetingDownload the poster herePoster Presentation

Published 22 January 2020
Categorized as -others, 2020, Publication

Non-clinical and clinical safety of MVA-based immunotherapy products targeting cancer and infectious diseases

https://www.transgene.com/wp-content/uploads/posters/Poster-actox2019.pdf Clémentine Spring-Giusti et al. American College of Toxicology – 40th Annual Meeting Download the poster here Poster Presentation

Published 17 November 2019
Categorized as -others, 2020, Publication

Meta analysis of two phase 1b randomized, double blind, placebo controlled clinical trials of the HBV therapeutic vaccines TG1050 and T101 developed in Europe/Canada or China

Poster 0710-AASLD 2019-TG1050-T101_MetaanalyseFabien Zoulim et al.AASLD 2019Download the poster herePoster Presentation

Published 8 November 2019
Categorized as -others, 2019, Publication, TG1050

Oncolytic Vaccinia virus contains a potent CD80/CD86 ligand whose deletion confers higher tolerance, and potential synergy with immune arming

Transgene SITC 2019 PosterJean-Baptiste Marchand et al.SITC 2019Download the poster herePoster Presentation

Published 6 November 2019
Categorized as -others, 2019, Invir.IO, Publication

Phase Ib/II trial of tipapkinogene sovacivec (TG4001), a therapeutic human papillomavirus 16-vaccine, in combination with avelumab in patients with advanced human papillomavirus 16-positive cancers

C. Le Tourneau, et al.European Journal of Cancer, July 2023 (191)Access the article herePublication

Published 30 September 2019
Categorized as -others, 2023, Publication, TG4001, TG4001

Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic HPV16 positive cancers

Christophe Le Tourneau et al.ESMO 2019Download the poster herePoster Presentation

Published 27 September 2019
Categorized as -others, 2019, 2025, Publication, publication key en, TG4001, TG4001, TG4050

The efficacy and safety of Tipapkinogen Sovacivec (TG4001) therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up

B. Grellier, et al. ESMO-AI 2025 Abstract available on ESMO-AI website – Download the abstract – Download the Poster

Published 18 April 2019
Categorized as -others, 2019, Publication, publication key en, TG4001, TG4001

The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism

Johann Foloppe, et al. Molecular Therapy Oncolytics, March 2019 – Download the article Publication

Published 27 March 2019
Categorized as -others, 2019, Publication, TG6002

Posts pagination

Newer posts Page 1 … Page 7 … Page 13 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu